Lercanidipine

Research use only, not for human use.

Lercanidipine is a calcium channel blocker of the dihydropyridine class.

Lercanidipine is a calcium channel blocker of the dihydropyridine class.

——

Animal Model:Albino male Wistar rats, middle cerebral artery occlusion (MCAo) modelDosage:1, 0.5 and 0.25 mg/kg Administration:Intraperitoneal injection (i.p.), acute administrationResult:Showed neuroprotective effect in focal cerebral ischemic-reperfusion injury model, most effective dose was found to be at 0.5 mg/kg. Significantly attenuated percentage infarct volume, significantly improved the apparent diffusion coefficient. Declined MMP-9 activity significantly in all Lercanidipine treated groups till 240 min post-reperfusion, while MMP-2 activity was inhibited only till 120 min post-reperfusion. Decreased caspase-3 activity significantly in Lercanidipine 15 and 120 min post-reperfusion groups only. Exhibited significant reduction in caspase-9 activity in all groups except at 240 min post-reperfusion group.Animal Model:Male SHRs Dosage:1.92, 0.96, 0.48, 0.24 and 0.12 mg/kg Administration:Oral gavage (p.o.), acute administration Result:Increased the AOC values of mean arterial pressure in a dose-dependent manner (285.4 mmHg×hour for 1.92 mg) as well as decreased BP.

Lercanidipine, Lercadip, Lerdip, Zanidip, REC-15-2375

GPCR/G Protein

Calcium Channel

Calcium Channel

Cardiovascular Disease

——

100427-26-7

611.73

C36H41N3O6

>98% (HPLC)

DMSO: 10 mM

CC1=C(C(OC)=O)C(C2=CC([N+]([O-])=O)=CC=C2)C(C(OC(C)(CN(CCC(C3=CC=CC=C3)C4=CC=CC=C4)C)C)=O)=C(C)N1

3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

(-20℃)

With Ice Pack

≥ 2 years